381 related articles for article (PubMed ID: 9150246)
1. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
[TBL] [Abstract][Full Text] [Related]
2. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
van Vliet AK; Nègre-Aminou P; van Thiel GC; Bolhuis PA; Cohen LH
Biochem Pharmacol; 1996 Nov; 52(9):1387-92. PubMed ID: 8937448
[TBL] [Abstract][Full Text] [Related]
3. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
4. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
7. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
8. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
9. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Del Puppo M; Rauli S; Galli Kienle M
Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
13. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Hughes AD
J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Tesfamariam B; Frohlich BH; Gregg RE
J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
[TBL] [Abstract][Full Text] [Related]
15. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Veerkamp JH; Smit JW; Benders AA; Oosterhof A
Biochim Biophys Acta; 1996 Apr; 1315(3):217-22. PubMed ID: 8611662
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Hidaka Y; Eda T; Yonemoto M; Kamei T
Atherosclerosis; 1992 Jul; 95(1):87-94. PubMed ID: 1642695
[TBL] [Abstract][Full Text] [Related]
18. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
19. Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro.
van Vliet AK; van Thiel GC; Naaktgeboren N; Cohen LH
Biochim Biophys Acta; 1996 Jun; 1301(3):237-41. PubMed ID: 8664334
[TBL] [Abstract][Full Text] [Related]
20. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
Sindermann JR; Fan L; Weigel KA; Troyer D; Müller JG; Schmidt A; March KL; Breithardt G
Atherosclerosis; 2000 Jun; 150(2):331-41. PubMed ID: 10856525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
